Previous Statements by GERN
» Geron CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Geron Corporation Q2 2010 Earnings Call Transcript
» Geron Corporation Q1 2010 Earnings Call Transcript
OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Geron (GERN) announced on Monday that it agreed to a licensing deal with Janssen Pharmaceuticals worth $80 million.